

## 340B Rebate Model Would Reduce Access to Care in Rural and Remote Communities October 2025

**Community Health Centers Rely on 340B to Keep Americans Healthy.** For over three decades, the 340B program has supported health centers' efforts to ensure every American can afford life-saving medication and essential health services that decrease preventable ER visits, hospital admissions and long-term health care spending.

**HRSA Should Exempt Community Health Centers from the 340B Rebate Model Pilot Program.** Health centers are safety net providers operating on razor thin margins. A sudden increase in upfront 340B prices will reduce the number of drugs a health centers can stock, make it incredibly difficult for health centers to finance affordable medications at the pharmacy counter, and limit wraparound services essential to improve patient care.

**The Rebate Model Would Cause Large Price Hikes on 340B Medications.** Higher upfront costs for health centers will cause patients to lose access to essential, life-sustaining medications.

Drug	Upfront Price Increase	What the Medication Does
Eliquis	6,234%	Blood thinners to prevent blood clots and strokes. These are vital life savings therapies that keep patients out of the ER and the hospital.
Xarelto	135,933%	
Farxiga	725%	These medications help manage blood sugar levels in adults with type 2 diabetes. They are a mainstay of primary care treatment for diabetes, chronic kidney disease, heart failure, and prevention of cardiovascular disease.
Jardiance	209,682%	
Januvia	1,044%	Helps manage high blood sugar levels in adults with type 2 diabetes.
Novolog	315%	Fast acting insulin to control high blood sugar in patients with type 1 and type 2 diabetes.

**The Rebate Model Will Worsen the Burden of Chronic Disease.** Health centers use the medications in the proposed rebate model to treat diabetes, stroke, heart disease and other chronic conditions. Restrictions on 340B could cause more than 3 million health center patients to lose access to care and trigger closures and layoffs.<sup>1</sup>

**CHC Provider Testimonial:** *For the 30 uninsured patients currently enrolled in our 340B assistance program and receiving these medications, the [rebate model would be] devastating. Their out-of-pocket cost for a 30-day supply would jump from roughly \$6 to more than \$500—an impossible financial burden for both our patients and our organization. For these individuals, the consequences are immediate: uncontrolled blood sugars leading to diabetic complications, untreated rheumatoid arthritis resulting in disability, and interruption of anticoagulation therapy leading to strokes, pulmonary embolisms, or even death.* – Third Street Health Center in Mansfield, Ohio.

If you are interested in learning more, you can read NACHC's full comment letter [here](#).

<sup>1</sup> <https://www.headvocacy.org/wp-content/uploads/2023/02/NACHC-340B-Report-Summary-June-2022.pdf>